Find Clinical Trial

Phase I/II trial of S 81694 administered intravenously in combination with paclitaxel to evaluate the safety, pharmacokinetic and efficacy in metastatic breast cancer


← Back
Study Phase Phase 1-2
Therapeutic Area Oncology
Active Substance S081694
SponsorInstitut de Recherches Internationales Servier (I.R.I.S)
Active Substance CodeS081694
Protocol CodeCL1-81694-003
EudraCT Code2017-002459-27
NCT CodeNCT03411161


Documents and links

Results are not yet available.




Servier Glossary of Terms

To ease the reading, we are developing a glossary of terms. In this glossary, we provide the lay terms used in our lay summaries and the corresponding medical terms. You will find the Servier Glossary of Terms on this link.



© 2017 LES LABORATOIRES SERVIER, an incorporated company of Servier.
All Rights Reserved. Servier does not sell its products over the Internet.
More information

Report a side-effect with a drug.